Cascading adoptive cell therapy for metastatic melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 401-406

  Su, Xiaosan ^a   Zhang, Lei ^a   Wu, Shangmin ^a   Jin, Liangkun ^a   Ye, Junsong ^a   Guan, Zheng ^a   Chen, Rui ^a  

^a First Hospital of Kunming   (China)

Author keywords

adoptive cell therapy; cytokine induced killer cell; melanoma; tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; AGED; ANAMNESIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CELL THERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

AGED; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS; REMISSION INDUCTION; SKIN NEOPLASMS; TISSUE THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79960051896     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0947     Document Type: Article

References (34)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998.
2. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159.
3. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233.
4. Su XS, Zhang L, Jin LK, et al. Immunotherapy with cytokineinduced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm 2010;25:465.
5. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26:332.
6. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008;31:742.
7. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105.
8. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor- infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676.
9. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346.
10. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8 + T cell immunity against a tumor/self-antigen is augmented by CD4 + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591.
11. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. J Exp Med 2005;202:907.
12. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling. J Clin Invest 2007;117:2197.
13. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139.
14. Lu PH, Negrin RS. A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687.
15. Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:181.
16. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol Oncol 2009; 27:130.
17. Blazer DG 3rd, Sondak VK, Sabel MS. Surgical therapy of cutaneous melanoma. Semin Oncol 2007;34:270.
18. Coffey JC, Wang JH, Smith MJ, et al. Excisional surgery for cancer cure: Therapy at a cost. Lancet Oncol 2003;4:760.
19. Demicheli R, Retsky MW, Hrushesky WJ, et al. The effects of surgery on tumor growth: A century of investigations. Ann Oncol 2008;19:1821.
20. Bellone G, Novarino A, Vizio B, et al. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. Int J Oncol 2009;34:1701.
21. Galley HF, DiMatteo MA, Webster NR. Immunomodulation by anaesthetic, sedative and analgesic agents: Does it matter? Intensive Care Med 2000;26:267.
22. Koltun WA, Bloomer MM, Tilberg AF, et al. Awake epidural anesthesia is associated with improved natural killer cell cytotoxicity and a reduced stress response. Am J Surg 1996; 171:68.
23. Hashimoto T, Hashimoto S, Hori Y, et al. Epidural anaesthesia blocks changes in peripheral lymphocytes subpopulation during gastrectomy for stomach cancer. Acta Anaesthesiol Scand 1995;39:294.
24. Schlagenhauff B, Ellwanger U, Breuninger H, et al. Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res 2000;10:165.
25. Klein HG. Immunomodulatory aspects of transfusion: A once and future risk? Anesthesiology 1999;91:861.
26. Carter JJ, Whelan RL. The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin North Am 2001;10:655.
27. Kaseda S, Aoki T, Hangai N, et al. Better pulmonary function and prognosis with video-assisted thoracic surgery than with thoracotomy. Ann Thorac Surg 2000;70:1644.
28. Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. World J Surg 2000;24:27.
29. Tschernko EM, Hofer S, Bieglmayer C, et al. Early postoperative stress: Video-assisted wedge resection/lobectomy vs conventional axillary thoracotomy. Chest 1996;109: 1636.
30. Yim AP, Wan S, Lee TW, et al. VATS lobectomy reduces cytokine responses compared with conventional surgery. Ann Thorac Surg 2000;70:243.
31. Leaver HA, Craig SR, Yap PL, et al. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest 2000;30:230.
32. Su XS, Guo SJ, Zhou CX, et al. A simple and effective method for cancer immunotherapy by inactivated allogeneic leukocytes infusion. Int J Cancer 2009;124:1142.
33. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356:802.
34. Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009;41:36.